Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Paper cited by two bottleneck pages and eleven idea pages, indexed on Europe PMC as PubMed record 35145263 and published in Nature Reviews Drug Discovery; the citing pages link this DOI, which is how the record was matched.
Overview
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 35145263 (DOI 10.1038/d41573-022-00030-4). Matched by DOI alone: two bottleneck pages and eleven idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
Two bottleneck pages and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- IdeaA billion-dollar prize for the first durable cure of a lethal metastatic cancer
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares Patent term extension scaled to proven survival gain, Outcome-based annuity payments for potentially curative one-time therapies, Incentives reward me-too drugs and marginal gains.
- IdeaPatent-free open-source development of repurposed and off-patent cancer drugs
Shares A repurposing label pathway with short exclusivity that non-profits can hold, Incentives reward me-too drugs and marginal gains.
- IdeaPublic co-investment in first-in-class phase 1 with a royalty return
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA legal right to obtain marketed cancer drugs at cost for combination trials
Shares Require head-to-head trials against the best in class for later entrants, Too many combinations to test.
- IdeaTransferable priority vouchers for first-in-class drugs, with price conditions
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaA non-profit pharmaceutical company for the cancers markets ignore
Shares A repurposing label pathway with short exclusivity that non-profits can hold, Incentives reward me-too drugs and marginal gains.
- IdeaPayers fund trials of cheaper, shorter or lower-dose versions of expensive treatments
Shares Extra exclusivity for sponsors who run treatment-duration and de-escalation trials, Incentives reward me-too drugs and marginal gains.